BELGRAVIA CAPITAL adds to expertise in corporate development and expands medical advisory committee
March 12 2018 - 7:00AM
BELGRAVIA CAPITAL INTERNATIONAL INC. (CSE:BLGV) (OTCQB:BLGVF)
(“Belgravia Capital”, “Belgravia”, or the “Company”) is pleased to
announce senior additions to its management team. Dr. Shoaib
Sheikh, is joining as medical advisor, and Mr. Jason Batista is
joining as Director of Corporate Development.
Dr. Shoaib Sheikh is joining the medical
advisory committee of Belgravia. Dr. Sheikh, a physician, is
an accomplished laparoscopic surgeon and the Chair of the
Technology Committee of the American Association of Hand
Surgeons. He has also studied the management of health care
delivery and high performance healthcare leadership at Harvard
Business School.
Mr. Mehdi Azodi, President and
Chief Executive Officer of the Company stated: “Dr.
Sheikh’s leadership skills will enhance our ability to execute in
planned commercial developments in the Cannabidiol (“CBD”)
space. We are carefully advancing opportunities in this
space. Dr. Sheikh is joining Dr. Sam Hanna on the medical
advisory committee. Dr. Hanna, a recognized Canadian
dermatologist, is assisting the Company in its development of
opportunities in the Cannabidiol commercial space. We plan to
shortly provide details regarding Belgravia-financed and
Belgravia-led dermatological product developments in both the
cosmetic and medicinal areas of this space.”
The Company is also pleased to announce that Mr.
Jason Batista has also joined Belgravia as Director of Corporate
Development. His education includes financial management and
advanced courses in financial planning. Since 2002 he has
worked as an investment advisor for two Canadian bank owned
investment dealers. He will be working with Mr. Mehdi Azodi, the
President and Chief Executive Officer of the Company, in reviewing
and managing the investment portfolio.
As described in the Company’s press release of
October 17, 2017, the Company, through a royalty streaming
division, holds an interest in anticipated water royalties, which
may be earned from the sales of water rights in the state of New
Mexico. Belgravia expects to provide specific terms regarding
the water royalties by the third quarter of
2018.
Belgravia’s business model includes actively
developing commercial opportunities in the legal cannabis space
such as taking CBD concepts through to medical products, making
shorter term investments in the legal medical cannabis space, and
making investments in other spaces unrelated to cannabis, but on an
opportunistic basis. Water royalty revenues would fall
into the later model of value creation for Belgravia
shareholders.
About Belgravia
CapitalBelgravia Capital International is focused on the
provision of value-added services to the international legal
Cannabis industry. The strategy is based on investing in
international licit cannabis growth companies on a selective basis,
and supporting the genesis and development of novel products and
marketing concepts in the Cannabis space. Software
developments include quality product attestation and loyalty
program platforms. Investments will include developing
licensed producers and distributors and product developers.
Belgravia Capital intends to establish joint
research and development partnerships with Licensed Producers
operating under ACMPR regulations in Canada and in other
jurisdictions where medicinal cannabis is fully legal. Belgravia
Capital may invest in various private and public companies in other
industry sectors on an opportunistic basis. For more information,
please visit www.belgraviacapital.ca.
Forward-Looking
Statements Certain information set forth in this news
release may contain forward-looking statements that involve
substantial known and unknown risks and uncertainties and other
factors which may cause the actual results, performance or
achievements of the Company to be materially different from any
future results, performance or achievements expressed or implied by
such forward-looking statements. Forward-looking statements include
statements that use forward-looking terminology such as “may”,
“will”, “expect”, “anticipate”, “believe”, “continue”, “potential”
or the negative thereof or other variations thereof or comparable
terminology. Such forward-looking statements include, without
limitation, statements regarding planned investment activities
& related returns, trends in the markets for fertilizers and
medicinal or recreational use of cannabis, the timing or assurance
of the legalization of recreational cannabis, the timing for
completion of research and development activities, the potential
value of royalties from water and other resources, and other
statements that are not historical facts. These forward-looking
statements are subject to numerous risks and uncertainties, certain
of which are beyond the control of the Company, including, but not
limited to, changes in market trends, the completion, results and
timing of research undertaken by the Company, risks associated with
resource assets, the impact of general economic conditions,
commodity prices, industry conditions, dependence upon regulatory,
environmental, and governmental approvals, the uncertainty of
obtaining additional financing, and risks associated with cannabis
use for medicinal or recreational purposes. Readers are cautioned
that the assumptions used in the preparation of such information,
although considered reasonable at the time of preparation, may
prove to be imprecise and, as such, undue reliance should not be
placed on forward-looking statements.
For More Information, Please
Contact:Mehdi Azodi, President & CEOBelgravia Capital
(416) 779-3268 mazodi@blgv.ca
Belgravia Hartford Capital (CSE:BLGV)
Historical Stock Chart
From Nov 2024 to Dec 2024
Belgravia Hartford Capital (CSE:BLGV)
Historical Stock Chart
From Dec 2023 to Dec 2024